Evidence map›Paper›PMID 40624990›Full record

Trial reportJournal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology2025

TROP2 Expression in Salivary Gland Adenoid Cystic Carcinoma (ACC) According to Histologic Subtype: Therapeutic Implications.

Juliana Mota Siqueira, Yoshitsugu Mitani, Mario L Marques-Piubelli, Camilla Oliveira Hoff, Flavia Bonini, Luana Guimaraes de Sousa, Mutsumi Mitani, Giovanna Lopes Carvalho, Fabio Daumas Nunes, Leandro Luongo Matos and 6 more

Registry-linked trialAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05884320 (Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05884320 phase2recruitingnot on this map

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

TypeinterventionalSponsorM.D. Anderson Cancer CenterRan2023 to 2028Enrolled30ConditionsGland, Salivary Gland CancersArmsSacituzumab Govitecan
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. TROP2 Expression in Salivary Gland Adenoid Cystic Carcinoma (ACC) According to Histologic Subtype: Therapeutic Implications.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2025
    Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Juliana Mota SiqueiraDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-5373-0141
Yoshitsugu MitaniDepartment of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-8661-4702
Mario L Marques-PiubelliDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-6324-2096
Camilla Oliveira HoffDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Flavia BoniniDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Luana Guimaraes de SousaDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Mutsumi MitaniDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Giovanna Lopes CarvalhoDepartment of Stomatology, Discipline of Oral and Maxillofacial Pathology, School of Dentistry, University of São Paulo, São Paulo, São Paulo, Brazil.ORCID https://orcid.org/0000-0001-9940-5590
Fabio Daumas NunesDepartment of Stomatology, Discipline of Oral and Maxillofacial Pathology, School of Dentistry, University of São Paulo, São Paulo, São Paulo, Brazil.ORCID https://orcid.org/0000-0002-7785-6785
Leandro Luongo MatosHead and Neck Surgery, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (Icesp, HCFMUSP), São Paulo, Brazil.
Shiaw-Yih LinDepartment of Systems Biology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Michael T SpiottoDepartment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ehab Y HannaDepartment of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Daniel J McGrailCenter for Immunotherapy and Precision Immuno-Oncology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Adel K El-NaggarDepartment of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Renata FerrarottoDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Adenoid Cystic Carcinoma Research FoundationDeWayne Everage Adenoid Cystic Carcinoma FundNCI NIH HHS P30 CA016672NIDCR NIH HHS HHSN268200900039CResearch Histology Core Laboratory NCI CA16672Ryan Smith Adenoid Cystic Carcinoma FundSalivary Gland Tumor Biorepository HHSN268200900039C 04U.S. Department of Defense W81XWH-21-0409Wold Foundation
6 · The paper itself

Abstract

backgroundAdenoid cystic carcinoma (ACC) is a common salivary gland carcinoma with high recurrence and distant metastasis rates. Currently, there is no standard systemic treatment available. TROP2 is a transmembrane glycoprotein involved in the oncogenesis of several tumors that can be therapeutically targeted by a TROP2-antibody-drug conjugate (ADC). We aimed to characterize TROP2 expression in ACC and assess TROP2 as a potential therapeutic target.

methodsTROP2 immunohistochemistry was performed in a tissue microarray including 165 ACC of salivary gland. The tumors were grouped according to the histological pattern as non-solid, solid + non-solid, or solid. TROP2 protein expression in ACC cell lines was assessed and subjected to drug screening with TROP2-ADC.

resultsTROP2 expression was high in 59%, moderate in 30%, weak in 8%, and negative in 3% of cases. TROP2 expression was significantly higher in non-solid compared with solid or solid + non-solid (p < 0.001). Notably, TROP2 expression was heterogenous among the dual cellular component, with TROP2 expression identified predominantly in the ductal and not in the myoepithelial cells. In vitro drug screening demonstrated that TROP2-ADC had selective anti-tumor effect in TROP2 expressing ACC cells.

conclusionsTROP2 expression is prevalent in ACC, particularly in the ductal cell component of the non-solid tumors. The pre-clinical drug screening findings provide a biological rationale for exploring TROP2 as a therapeutic target in TROP2-expressing ACC.

trial registrationclinicaltrials.gov: NCT05884320; NCI-2023-04260.

Indexed as

Antigens, NeoplasmCarcinoma, Adenoid CysticCell Adhesion MoleculesSalivary Gland NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorCell Line, TumorFemaleHumansImmunoconjugatesImmunohistochemistryMaleMiddle AgedTissue Array AnalysisAntigens, NeoplasmBiomarkers, TumorCell Adhesion MoleculesImmunoconjugatesTACSTD2 protein, humanADCadenoid cystic carcinomaantibody–drug conjugateimmunohistochemistrysacituzumab govitecanSN‐38TROP2

Identifiers

PMID40624990
PMCPMC12419983

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.